Slide 1: Highlights FY2026 and Outlook for FY2027
For personal use only Highlights FY2026 Outlook for FY2027 May 2026
Slide 2: Who is TruScreen
For personal use only Who is TruScreen Enabled by AI, TruScreen provides an accurate, real time cervical cancer screening solution
Slide 3: TruScreen Group overview
TruScreen Group Ltd is a revenue generating Life Science company with a unique, AI-enabled real-time cervical cancer screening device. For personal use only FY26 annual sales exceeded NZD $2.4m - 42% YOY growth. TruScreen Group Ltd owns TruScreen Pty Ltd, the Australian operating company that manufa
Slide 4: The TruScreen Journey
The TruScreen Journey Building the Fundamentals 2014 - 2020 Building for the Future 2020-2024 2025 & Beyond For personal use only 2017 Dec 2018 Oct 2019 May 2022 2025 CFDA (NMPA) 523% sales Recognition by Managing COVID-19 challenges China Growth continues approval for second growth in H1 World Heal
Slide 5: TruScreen Sales Strategy
For personal use only TruScreen Sales Strategy
Slide 6: Device installations and SUS Sales: Key Financials
Device installations and SUS Sales KEY FINANCIALS FY 23 FY 24 FY25 FY26 Actual From FY25 to FY26: NZD (m) Actual Actual Actual (unaudited) For personal use only Sales 1.66 2.1 1.7 2.4 Total Revenue 2.2 2.6 2.1 2.8 ⚫ Sales increased 42% YOY COGS 1.3 1.4 1.2 1.7 R&D 0.9 0.9 0.8 0.9 ⚫ SUS Sales increas
Slide 7: FY25 actual vs FY26 unaudited sales
FY25 ACTUAL FY26 ACTUAL NZ$1.7m Unaudited sales NZ$2.4m For personal use only 7
Slide 8: Recurring Revenue Model
Recurring Revenue Model • TruScreen manufactures two devices – o one made in China for use in China, where locally manufactured products For personal use only have preferential market access o one made in Australia for other markets • For each patient screened with the TruScreen device a new disposa
Slide 9: TruScreen Sales Strategy
TruScreen Sales Strategy • Whilst many other medical technology companies seek to commercialize their devices in developed countries, TruScreen focuses on Low and Middle Income Countries (LMICs) For personal use only such as China, Mexico, Vietnam, India, Indonesi and Zimbabwe. • Working with global
Slide 10: TruScreen Regulatory Approvals
TruScreen Regulatory Approvals International Quality Recognized by International Approvals: Accreditation: • World Health Organisation (WHO) • CE Mark, European Union • ISO 13485 For personal use only • NMPA, China • UNITAID • IEC 60601-1 • TGA, Australia • Clinton Health Access Initiative • IEC 606
Slide 11: Global presence
Global presence Registration and Sales activity in Russia, Kazakhstan, Kyrgyzstan, Armenia and Belarus Uzbekistan product registration completed to enable the validation trial of TruScreen for a national cervical cancer Inclusion in Chinese Obstetricians and screening program Gynecologists Associati
Slide 12: TruScreen Highlights FY 2026
For personal use only TruScreen Highlights FY 2026
Slide 13: FY2026 Highlights — Five Marquee Wins
FY2026 Highlights — Five Marquee Wins 01 260,000-woman Vietnam programme 02 India re-entry 03 BMC Cancer landmark study 5-year cervical cancer screening programme Renovate Biologicals Pvt Ltd appointed as 14,982 women, 64 hospitals, 9 provinces. CIN2+ launched in Ho Chi Minh City with HPHA & Gorton
Slide 14: A Diversified Global Footprint
A Diversified Global Footprint Active markets Launching FY27 Pipeline / new signings For personal use only ■ South Africa (AIR · pilot study) ■ China (61.3% of FY26 sales) ■ India (regulatory approval pending) ■ Uzbekistan (Albatros Health Care) ■ Vietnam (4 public hospitals + private) ■ Indonesia (
Slide 15: China — The Anchor Market
China — The Anchor Market 61.3% Landmark BMC Cancer publication · Feb 2026 14,982 64 9 For personal use only women hospitals provinces of FY2026 product sales Clinical performance vs Liquid-Based Cytology & hrHPV Consumable sales volumes met expectations despite challenging economic conditions. 87%
Slide 16: Vietnam & Indonesia — South-East Asia Growth Engine
Vietnam & Indonesia — South-East Asia Growth Engine Vietnam Indonesia 260,000 95M For personal use only women to be screened in Ho Chi Minh City over 5 years (with HPHA & Gorton women of screening age — government-funded mass screening program Health Services) creates enormous opportunity ■ Adopted
Slide 17: India Re-Entry & South-East Asia Regulatory Progress
India Re-Entry & South-East Asia Regulatory Progress India Renovate Biologicals Pvt Ltd appointed distributor (Apr-25). Interim product testing licence (Jul-25) — 10 devices 468M shipped. Regulatory submission filed Apr-26, approval expected within 3-6 months. Consortium of private hospitals lined u
Slide 18: Africa — Three Growth Stories
Africa — Three Growth Stories Zimbabwe South Africa Nigeria 20,000 Jul 26 Gates For personal use only screenings planned in CY2026 SAHPRA approval expected Foundation grant application Re-validation by the National Microbiology New distributor AIR appointed (Nov-25). Product Collaboration with LASUT
Slide 19: Central Asia, LatAm & New Distributors
Central Asia, LatAm & New Distributors Uzbekistan Central Asia Albatros Health Care LLC appointed (May-26) a IMSystem multi-centre clinical study to secure NZD 1.26m leading medical device distributor. Pilot clinical study commencing June 2026 with ethics 2,000 recognition as a primary screening met
Slide 20: UNITAID — A Step-Change Opportunity
UNITAID — A Step-Change Opportunity 14 1Bn US$18.4m For personal use only high-burden countries addressable screening-age potential revenue to TruScreen across Africa, Asia-Pacific & LatAm women across target geographies as consortium lead Why TruScreen fits the UNITAID brief ■ Point-of-care, portab
Slide 21: Clinical & Scientific Milestones
Clinical & Scientific Milestones Jan 2025 May 2025 Jan 2026 WHO AI Collaboration Saudi Arabia study Pregnancy safety For personal use only TruScreen invited to present at WHO Global AI Published Saudi Arabia study confirms TruScreen Clinical study validates TruScreen efficacy and safety Collaboratio
Slide 22: Commercial & Distributor Expansion
Commercial & Distributor Expansion Asia-Pacific Africa & Middle East Pipeline & Studies Jan 2025 Nov 2025 Feb 2025 For personal use only Indonesia distributor appointed (95M women). South Africa — AIR Group appointed as distributor. MOU with Hangzhou Dalton Bioscience. Apr 2025 Mar 2026 Aug 2025 Ind
Slide 23: TruScreen Outlook: FY2027 & Growth Strategies
For personal use only TruScreen Outlook: FY2027 & Growth Strategies
Slide 24: What's Coming Next
What’s Coming Next FY2027 outlook Catalyst Drivers India Full regulatory approval expected within 3–6 H2 CY2026 India regulatory approval; first commercial shipments. months of Apr-26 filing. For personal use only South Africa SAHPRA approval expected Jul 2026; pilot study to follow. H2 CY2026 South
Slide 25: Growth Strategies
Growth Strategies Market expansion to continue with China the key focus For personal use only Focus on key growth provinces (Shandong, Jiangsu,, Hunan, Zhejiang, Guangdong, Guangxi) - Total population 496m Enter huge African market collaborating with NGOs Strengthen vertical Asian market from Indone
Slide 26: For personal use only
Build on International NGO Recognition (WHO, UNITAID, CHAI, COGA , CSCCP) to build acceptance and remove barriers to sale Focus on countries with limited or nil cervical screening capability For personal use only Developing strategic partnerships for complementary woman’s health services Capitalise
Slide 27: The Game Changer
The Game Changer The timeline compression of WHO’s 1 For personal use only 90-70-90 milestones1 to December 2030 - Sense of Urgency UNITAID and global NGOs 2 funding by late 2026 to drive cervical cancer screening 1 https://www.who.int/initiatives/cervical-cancer-elimination-initiative 27
Slide 28: TruScreen Market Potential
TruScreen Market Potential For personal use only 28
Slide 29: DaltonBio Strategic Alliance
DaltonBio Strategic Alliance • Q4 FY25 - Memorandum of Understanding signed with Dalton Biosciences (DaltonBio) For personal use only • Q1 FY26 - TruScreen and Dalton Bio sign Distribution Agreement for HPV products in India 1. TruScreen to be appointed a global distributor of DaltonBio HPV related
Slide 30: Thank you
Thank you. For personal use only Tony Ho Guy Robertson Executive Chairman Chief Financial Officer E – tonyho@truscreen.com E – guyrobertson@truscreen.com TruScreen Suite 3.03 18 Orion Rd Lane Cove West NSW 2066 Australia www.truscreen.com
Slide 31: Disclaimer
Disclaimer This presentation has been prepared by TruScreen Group Limited (the “Company”) and is dated 25 August 2023. This presentation contains summary information about the Company and its activities which is current as at the date of this presentation. The information in this presentation is of